Fatty acid oxidation disorders are classified under rare and genetic disorders. In fatty acid oxidation disorder, the body is unable to produce or utilize particle enzyme which is required for oxidation of fatty acids. Absence of enzymes stops the breakdown of fatty acids and it’s eventually build up in the liver and other internal organs. Fatty acid oxidation disorder leads to the body being unable to produce energy from fatty acids in the liver and muscles. People with fatty acid oxidation disorder can function normally with dietary adjustments and medications. According to the National Institutes of Health (NIH), the incidence of fatty acid oxidation disorder is 1 in 5,000-10,000 births globally.
Increased focus on determining coronavirus cure among leading biopharmaceutical companies lead to delay in research and development activities of fatty acid oxidation disorder market. There has been observed supply chain disruption due to restrictions laid on trading across borders by various countries. The significant decline in hospital visits and treatment-seeking rates will have a temporary impact on fatty acid oxidation disorder market. Covid-19 has led to lockdown in several countries delaying manufacturing activities of fatty acid oxidation disorder market.
To remain ‘ahead’ of your competitors, request for a sample here@ https://www.persistencemarketresearch.com/samples/32009
Fatty Acid Oxidation Disorder Market: Drivers and Restraints
The rise in the prevalence of rare and genetic disorders increases the demand for fatty acid oxidation disorder market. Increasing funding for research and development from leading biopharmaceutical companies is expected to fuel fatty acid oxidation disorder market growth. For instance, in July 2020, Ultragenyx Pharmaceutical Inc., a market player in drug development for rare disorders announced U.S. Food and Drug Administration (FDA) approval of triheptanoin, a new drug used in the treatment of fatty acid oxidation disorder. Advancement in technology and research and development activities is expected to fuel fatty acid oxidation disorder market growth. Lack of awareness about therapeutic options available for rare disorders is expected to hinder fatty acid oxidation disorder market growth. The stringent regulatory requirement for drug approval is a challenging factor for fatty acid oxidation disorder market growth.
Fatty Acid Oxidation Disorder Market: Segmentation
Based on the drug type, the global fatty acid oxidation disorder market can be segmented as:
Based on the route of administration, the global fatty acid oxidation disorder market is segmented as:
Based on the distribution channel, the global fatty acid oxidation disorder market is segmented as:
- Hospital pharmacies
- Retail pharmacies
- Drug stores
- Online stores
Fatty Acid Oxidation Disorder Market: Overview
Levocarnitine hold the majority of revenue share in fatty acid oxidation disorder market with the highest demand. Oral drugs are most common in fatty acid oxidation disorder market generating maximum revenue. Whereas, intravenous route of administration will observe a significant rise in demand with the development of injectable drugs in the fatty acid oxidation disorder market. Hospital pharmacies contribute the largest share among the distribution channel in fatty acid oxidation disorder market. Online pharmacies will observe a significant rise in demand with increased market penetration in fatty acid oxidation disorder market.
Fatty Acid Oxidation Disorder Market: Region-wise Outlook
North America is expected to dominate the fatty acid oxidation disorder market during the forecast period with a high rate of approval and commercialization. Increased prevalence of genetic and rare disorders makes Europe lucrative for fatty acid oxidation disorder market. Asia-Pacific is expected to observe the highest growth rate in fatty acid oxidation disorder market in the coming decade with increasing domestic manufacturers. Increasing diagnostic and treatment-seeking rate among the population in Asia-Pacific makes it lucrative for fatty acid oxidation disorder market growth. Middle-East and Africa are least lucrative in fatty acid oxidation disorder market with low per capita healthcare expenditure and poor economic conditions.
Fatty Acid Oxidation Disorder Market: Key Market Participants
Major players in fatty acid oxidation disorder market include Biosynth AG, Daiichi Sankyo Ltd., Northeast Pharmaceutical Group Co., Ltd., Merck KGaA, Mylan Laboratories Limited, AminoScience LLC, Chengda Pharmaceuticals Co. Ltd., Sigma-Tau Pharmaceuticals, Bedford Laboratories, Spectrum Chemicals and Laboratory Products, Inc., and others.
The research report on fatty acid oxidation disorder market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on fatty acid oxidation disorder market provides analysis and information according to market segments such as drug type, route of administration, distribution channel, and region.
You can access Full report here @ https://www.persistencemarketresearch.com/checkout/32009
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws on its multi-disciplinary capabilities and a high pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Persistence Market Research stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, its engagement models are highly flexible without compromising on its deep-seated research values.
New York City, NY 10007
U.S.A – Canada Toll-Free: 800-961-0353